GENPHARMASEC
|
GENPHARMASEC Last 5 Year Financial Ratios History
[Standalone]
| Mar2024 | Mar2023 | Mar2022 | Mar2021 | Mar2020 | |
|---|---|---|---|---|---|
| Operational & Financial Ratios | |||||
| Earnings Per Share (Rs) | - | 0.04 | -0.01 | 0.06 | 0.05 |
| CEPS(Rs) | - | 0.02 | -0.01 | 0.04 | 0.03 |
| DPS(Rs) | - | - | - | - | - |
| Book NAV/Share(Rs) | 1.17 | 0.55 | 0.56 | 0.68 | 0.81 |
| Tax Rate(%) | 90.10 | -299.43 | 52.74 | 16.70 | 16.26 |
| Margin Ratios | |||||
| Core EBITDA Margin(%) | 0.53 | 1.01 | -1.91 | 5.60 | 3.92 |
| EBIT Margin(%) | 2.83 | 1.32 | -1.62 | 7.08 | 7.30 |
| Pre Tax Margin(%) | 1.53 | 1.10 | -1.62 | 7.08 | 7.30 |
| PAT Margin (%) | 0.15 | 4.41 | -0.77 | 5.90 | 6.12 |
| Cash Profit Margin (%) | 0.21 | 4.49 | -0.71 | 5.96 | 6.15 |
| Performance Ratios | |||||
| ROA(%) | 0.10 | 5.53 | -0.85 | 4.78 | 4.35 |
| ROE(%) | 0.12 | 7.33 | -1.39 | 7.81 | 5.36 |
| ROCE(%) | 2.00 | 2.00 | -2.46 | 7.61 | 5.93 |
| Asset Turnover(x) | 0.68 | 1.25 | 1.10 | 0.81 | 0.71 |
| Sales/Fixed Asset(x) | 187.34 | 175.85 | 267.06 | 339.92 | 521.38 |
| Working Capital/Sales(x) | 0.81 | 1.51 | 1.79 | 1.09 | 1.62 |
| Efficiency Ratios | |||||
| Fixed Capital/Sales(x) | 0.01 | 0.01 | - | - | - |
| Receivable days | 88.89 | 86.95 | 93.34 | 124.69 | 78.18 |
| Inventory Days | 111.15 | 139.93 | 117.36 | 95.42 | 76.53 |
| Payable days | 28.23 | 59.21 | 91.62 | 120.30 | 66.48 |
| Valuation Parameters | |||||
| PER(x) | 2,787.50 | 46.00 | - | 138.15 | 278.22 |
| PCE(x) | 1,963.11 | 75.24 | -780.09 | 136.79 | 276.87 |
| Price/Book(x) | 1.91 | 5.62 | 9.91 | 11.85 | 16.02 |
| Yield(%) | - | - | - | - | - |
| EV/Net Sales(x) | 3.56 | 3.42 | 5.51 | 7.99 | 16.86 |
| EV/Core EBITDA(x) | 123.13 | 244.10 | -351.28 | 111.81 | 229.90 |
| EV/EBIT(x) | 125.52 | 258.27 | -340.03 | 112.73 | 230.84 |
| EV/CE(x) | 1.60 | 4.74 | 6.96 | 6.12 | 11.24 |
| M Cap / Sales | 4.06 | 3.37 | 5.57 | 8.15 | 17.02 |
| Growth Ratio | |||||
| Net Sales Growth(%) | 19.16 | -6.61 | 28.22 | 29.13 | 4,298.73 |
| Core EBITDA Growth(%) | 145.80 | 183.28 | -128.18 | 25.75 | 320.55 |
| EBIT Growth(%) | 155.12 | 176.19 | -129.35 | 25.23 | 319.20 |
| PAT Growth(%) | -95.89 | 637.15 | -116.65 | 24.57 | 337.06 |
| EPS Growth(%) | -98.03 | 634.21 | -113.11 | 24.57 | -56.30 |
| Financial Stability Ratios | |||||
| Total Debt/Equity(x) | 0.05 | 0.20 | - | - | - |
| Current Ratio(x) | 14.85 | 9.17 | 3.43 | 3.74 | 2.78 |
| Quick Ratio(x) | 11.57 | 4.48 | 1.86 | 2.67 | 2.17 |
| Interest Cover(x) | 2.18 | 6.03 | - | - | - |
| Total Debt/Mcap(x) | 0.03 | 0.04 | - | - | - |
Compare Financial Ratios of peers of GENPHARMASEC
| Peers & Returns | Market Capitalization | 1 Week | 1 Month | 1 Year | ||
| GENPHARMASEC | ₹124.0 Cr | -10.8% | -27.3% | -53.6% | Stock Analytics | |
| SUDARSHAN CHEMICAL INDUSTRIES | ₹7,990.1 Cr | 4.7% | -7.4% | 91.8% | Stock Analytics | |
| KIRI INDUSTRIES | ₹3,561.9 Cr | 7.7% | 10% | 59.2% | Stock Analytics | |
| VIDHI SPECIALTY FOOD INGREDIENTS | ₹2,402.9 Cr | 2% | 2% | 17.7% | Stock Analytics | |
| BHAGERIA INDUSTRIES | ₹864.6 Cr | -2.3% | -3.1% | 25.1% | Stock Analytics | |
| BODAL CHEMICALS | ₹801.8 Cr | 4.6% | -4% | -23.2% | Stock Analytics | |
GENPHARMASEC Share Price vs Sensex
| Share Price Returns(%) | 1 Week | 1 Month | 1 Year |
| GENPHARMASEC | -10.8% |
-27.3% |
-53.6% |
| SENSEX | 0.5% |
0.3% |
7.9% |
You may also like the below Video Courses
